Entry Inhibitors of Hepatitis B and D Viruses

Yang Yang; Youhua Xie

doi:10.1007/978-981-16-8702-0_12

Entry Inhibitors of Hepatitis B and D Viruses

Adv Exp Med Biol. 2022:1366:199-205. doi: 10.1007/978-981-16-8702-0_12.

Authors

Yang Yang^{1

2}, Youhua Xie^{3

4}

Affiliations

¹ Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Shanghai Institute of Infectious Diseases and Biosecurity, Shanghai Medical College, Fudan University, Shanghai, China.
² Department of Medical Microbiology and Parasitology, School of Basic Medical Sciences, Shanghai Institute of Infectious Diseases and Biosecurity, Shanghai Medical College, Fudan University, Shanghai, China.
³ Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Shanghai Institute of Infectious Diseases and Biosecurity, Shanghai Medical College, Fudan University, Shanghai, China. yhxie@fudan.edu.cn.
⁴ Department of Medical Microbiology and Parasitology, School of Basic Medical Sciences, Shanghai Institute of Infectious Diseases and Biosecurity, Shanghai Medical College, Fudan University, Shanghai, China. yhxie@fudan.edu.cn.

PMID: 35412142
DOI: 10.1007/978-981-16-8702-0_12

Abstract

Human hepatitis B virus (HBV) and hepatitis D virus (HDV) cause acute and chronic infections. The latter poses a serious public health threat as it is the major cause of chronic hepatitis, liver failure, cirrhosis, and hepatocellular carcinoma (HCC). In nature, HBV and HDV have a narrow host range and highly hepatotropic, only infecting the hepatocytes of humans and a few primates. The elucidation of cell entry mechanism by HBV has made great progress in recent years, which strongly promotes the establishment of new HBV infection models and the development of viral entry inhibitors. The study of HBV entry inhibitors has culminated in the first direct antiviral treatment for HDV. This review provides a concise introduction on the progress of HBV/HDV entry inhibitors in the recent years.

Keywords: Entry inhibitors; Envelope proteins; HBV; Host receptor.

Publication types

Review

MeSH terms

Animals
Carcinoma, Hepatocellular*
Hepatitis B virus
Hepatitis B* / complications
Hepatitis B* / drug therapy
Hepatitis D* / complications
Hepatitis D* / drug therapy
Hepatitis Delta Virus
Liver Neoplasms* / etiology